Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. 01093
01093 logo

01093 Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy CSPC PHARMA (01093) Today? Analysis, Price Targets, and 2026 Outlook.

No data

No data

No data

No data

Growth

Profitability

Efficiency

Wall Street analysts forecast 01093 stock price to rise
0 Analyst Rating
0
Wall Street analysts forecast 01093 stock price to rise
0 Buy
0 Hold
0 Sell
0
Current: 9.020
sliders
Low
0
Averages
0
High
0
0
Current: 9.020
sliders
Low
0
Averages
0
High
0
Nomura
Buy
maintain
AI Analysis
2026-02-16
Reason
Nomura
Price Target
AI Analysis
2026-02-16
maintain
Buy
Reason
The analyst rating for CSPC PHARMA was maintained at "Buy" by Nomura due to several positive factors. The firm expects a 20% year-over-year revenue growth in 4Q25, slightly surpassing market consensus. Additionally, the anticipated increase in collaboration revenue and a higher gross profit margin contributed to the positive outlook. Nomura also raised its revenue and earnings forecasts for FY2025 and FY2026, which further supported the decision to elevate the target price from $9.11 to $12.04.
CICC
CICC
Outperform
maintain
$11 -> $12
2026-02-02
Reason
CICC
CICC
Price Target
$11 -> $12
2026-02-02
maintain
Outperform
Reason
The analyst rating for CSPC Pharma (01093.HK) is maintained at "Underperform" by BofAS due to sales pressure, despite the positive developments in their collaboration with AstraZeneca and the potential for milestone revenue recognition from their R&D pipeline. CICC, on the other hand, raised its target price to $12 and kept its rating at "Outperform," reflecting confidence in the company's earnings forecasts and innovative assets.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for 01093
Unlock Now

People Also Watch